Atrial Fibrillation (AF)Phase 3LILAC-TIMI 76NCT05712200
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
A Phase 3 study testing Abelacimab in people with Atrial Fibrillation (AF), run by Anthos Therapeutics, Inc. at 789 sites in 35 countries.
Trial summary
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Atrial Fibrillation (AF)
- What is being tested?
- Abelacimab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 2,500 participants
- Where
- 789 sitesin 35 countries
- Study dates
- 27 Dec 2022to 30 Dec 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Patient is able to understand and has provided written informed consent to participate in the trial
- Diagnosed Atrial Fibrillation (AF) or atrial flutter (documented on an electrocardiogram (ECG) or monitor recording)
- Age 65-74 and a CHA2DS2VASc ≥4 OR age ≥75 and a CHA2DS2VASc ≥3
- Patient is judged by the responsible physician to be unsuitable for oral anticoagulation because the risks outweigh the benefits or the patient is unwilling to take oral anticoagulation AND this determination was made prior to and independent of the study
- At least 1 bleeding risk factor such as severe renal insufficiency, planned daily use of antiplatelet medication for the duration of the trial, history of bleeding from a critical area, or other conditions associated with increased risk of bleeding such as chronic nonsteroidal anti-inflammatory drug (NSAID) use, frailty or multiple falls
- Patient is judged by the responsible physician to be unsuitable for left atrial appendage (LAA) closure or occlusion device, an approved device is not available, or the patient is unwilling to undergo the procedure AND this determination was made prior to and independent of the study
Who cannot join
- AF due to an ongoing acute reversible cause (e.g., cardiac surgery, pulmonary embolism (PE), untreated hyperthyroidism, alcohol use)
- Patients who within 60 days prior to randomization (1) received a vitamin K antagonists (VKA) (e.g., warfarin, phenprocoumon, acenocoumarol) or a direct oral anticoagulant (DOAC) such as, dabigatran, rivaroxaban, apixaban, or edoxaban or (2) were newly diagnosed with AF
- Patients with an intracranial or intraocular bleed within the 3 months prior to screening or any history of spontaneous intracerebral hemorrhage at any time in the absence of antithrombotic treatment
- Any stroke within 14 days before randomization or transient ischemic attack (TIA) within 3 days before randomization
- Mechanical heart valve or valve disease that is expected to require mechanical valve replacement intervention (surgical or invasive) during the course of the study
- Patients on dialysis at screening or who are planned to start dialysis within 6 months
- Other protocol defined Inclusion/Exclusion criteria may apply
Trial locations and contacts
789 sites in 35 countries. Contact the study team or a site near you to ask about taking part.
789 sites in 35 countries
United States174 sites, 133 recruiting
- Recruiting
Anthos Investigative Site 9931
Albany, New York, 12211
Shreya Shah, sshah@capitalcardiology.com
Eleonore Warren, ewarren@capitalcardiology.com
- Withdrawn
Anthos Investigative Site 1006
Alexandria, Louisiana, 71301
- Recruiting
Anthos Investigative Site 9928
Allen, Texas, 75013
Ahmed Ladak, ahmed@ntrarx.com
Muhammad Chaudhry
- Recruiting
Anthos Investigative Site 9934
Altamonte Springs, Florida, 32714
Megan Bodiford, mbodiford@heartorlando.com
Nandkishore Ranadive
- Withdrawn
Anthos Investigative Site 1084
American Fork, Utah, 84003
- Recruiting
Anthos Investigative Site 1095
Aurora, Colorado, 80045
Jennifer Golden, jennifer.golden@va.gov
Emily Hager, emily.hager@va.gov
- Recruiting
Anthos Investigational site 9961
Baltimore, Maryland, 21201
Beata Assadi, bassadi@som.umaryland.edu
Myounghee Lee, mlee@umm.edu
- Recruiting
Anthos Investigative Site 1039
Baltimore, Maryland, 21218
Keith Moyer, keith.t.moyer@medstar.net
Sunjeet Sidhu
- Recruiting
Anthos Investigative Site 9957
Baltimore, Maryland, 21229
Jeffrey Cole
- Recruiting
Anthos Investigational site 9965
Baltimore, Maryland, 21287
Nino Isakadze
- Recruiting
Anthos Investigative Site 1054
Bangor, Maine, 04401
Hunter Martin, hlmartiniv@northernlight.org
Alan Wiseman
- Recruiting
Anthos Investigative Site 9913
Beaumont, Texas, 77702
Ashley Pennington, apennington@nextstageclinical.com
Jorge Hernandez
- Recruiting
Anthos Investigative Site 9902
Beavercreek, Ohio, 45431
Sara Hicks, shicks@internalmedicinecare.com
Ingrid Brown
- Recruiting
Anthos Investigative Site 1040
Birmingham, Alabama, 35205
Ashley Gilmore, agilmore@uabmc.edu
Alain Bouchard, Dr.
- Recruiting
Anthos Investigational site 9939
Birmingham, Alabama, 35233
Fadi Hage
- Not yet recruiting
Anthos Investigative Site 9947
Birmingham, Alabama, 35243
Robin Eiland, robin.eiland@orlandohealth.com
Sarah Merkl, sarah.merkl@orlandohealth.com
- Recruiting
Anthos Investigative Site 1013
Boca Raton, Florida, 33486
Esthefany Jabbour, esthefany@fwdclinical.com
Samia Quadri, samia@fwdclinical.com
- Withdrawn
Anthos Investigative Site 1082
Boston, Massachusetts, 02124
- Recruiting
Anthos Investigative Site 9918
Boston, Massachusetts, 02215
Alexander Cermak, acermak@bidmc.harvard.edu
Catrina Crocianni, ccrocian@bidmc.harvard.edu
- Withdrawn
Anthos Investigative Site 1031
Bountiful, Utah, 84010
- Recruiting
Anthos Investigational site 9810
Bradenton, Florida, 34209
Mirabella Miranda, Mirabella.miranda@novaclinicalresearch.com
Ashok Krishnamurthy
- Withdrawn
Anthos Investigative Site 1074
Bristol, Pennsylvania, 19007
- Recruiting
Anthos Investigative Site 9905
Brooklyn, New York, 11217
Areeba Menon, amemon@ctntexas.com
Ijaz Ahmad
- Recruiting
Anthos Investigational site 9967
Bryan, Texas, 77802
Ricardo Gutierrez
- Withdrawn
Anthos Investigative Site 1065
Cary, North Carolina, 27518
- Recruiting
Anthos Investigative Site 1005
Charlotte, North Carolina, 28207
Emad Ghaly, eghaly1@gmail.com
Aamer Qureshi
- Recruiting
Anthos Investigational site 9954
Chattanooga, Tennessee, 37403
Patrick Stevens
- Recruiting
Anthos Investigational site 9818
Clearwater, Florida, 33756
Delia Johnson, delia.johnson@baycare.org
Rebecca Walker Ignasiak, rebecca.walker-ignasiak@baycare.org
- Recruiting
Anthos Investigative Site 1025
Clearwater, Florida, 33756
Carolyn Rembish, rembishc@cccheart.com
Michael Barry
- Recruiting
Anthos Investigative Site 1022
Clearwater, Florida, 33777
Teresa Jones, jonest@cccheart.com
Jorge Navas
- Recruiting
Anthos Investigative Site 9943
Dallas, Texas, 75243
Maaz Ghani, mghani@sunbeamresearch.com
Amer Suleman
- Recruiting
Anthos Investigative Site 9942
Dallas, Texas, 75254
Ambreen Ahmed, ambreen.ahmed@theintracare.com
Sri Sunkara, sri.sunkara@theintracare.com
- Recruiting
Anthos Investigative Site 9945
Dayton, Ohio, 45429
Eva Collins, eva.collins@primedphysicians.com
William Randall
- Recruiting
Anthos Investigative Site 1019
Daytona Beach, Florida, 32114
Jennifer Langdon, jlangdon@daytonaheart.com
Hanscy Seide
- Withdrawn
Anthos Investigative Site 1049
Denver, Colorado, 80218
- Recruiting
Anthos Investigative Site 9912
Durham, North Carolina, 27709
Lalitha Uppada, lalitha.uppada@science37.com
Ambarish Pandey
- Recruiting
Anthos Investigative Site 1091
El Paso, Texas, 79905
Paola Varelas, PaolaV@davidturbaymd.com
David Turbay
- Withdrawn
Anthos Investigative Site 1050
Elizabethton, Tennessee, 37643
- Recruiting
Anthos Investigational Site 9807
Elmer, New Jersey, 08318
Traci Vogt, tvogt@hearthousenj.com
Graze yeretzian, gyeretzian@hearthousenj.com
- Withdrawn
Anthos Investigative Site 1094
Englewood, New Jersey, 07631
- Recruiting
Anthos Investigational site 9968
Eunice, Louisiana, 70535
Rechell Barzas, rechell.barzas@careaccess.com
Stephanie Courville, stephanie.courville@careaccess.com
- Recruiting
Anthos Investigative Site 9915
Evansville, Indiana, 47714
Abigail Hudson, abigail.hudson@globalaes.com
Elizabeth Robb, elizabeth.robb@globalaes.com
- Recruiting
Anthos Investigational site 9812
Fall River, Massachusetts, 02721
Elizabeth Bacon, ebacon@neccr.com
Marc Bergeron, mbergeron@neccr.com
- Recruiting
Anthos Investigative Site 1018
Falls Church, Virginia, 22042
Lauren Hoffman, lhoffman@virginiaheart.com
Tariq Haddad
- Withdrawn
Anthos Investigative Site 1048
Fayetteville, North Carolina, 28314
- Recruiting
Anthos Investigational site 9814
Fort Mill, South Carolina, 29707
Vidyasri Rao, vidya@prpstudy.com
Deborah Shelton, debbie@prpstudy.com
- Recruiting
Anthos Investigational site 9817
Fredericksburg, Virginia, 22401
Romi Balasubramanian, romi.balasubramanian@mwh.com
Christopher Hospidales, christopher.hospidales@mwhc.com
- Withdrawn
Anthos Investigative Site 1057
Germantown, Tennessee, 38138
- Withdrawn
Anthos Investigative Site 1089
Gilbert, Arizona, 85296
- Recruiting
Anthos Investigative Site 9922
Golden, Colorado, 80228
David Bailey, dbailey@chvpc.com
Rachel Szeghy, rszeghy@chvpc.com
- Active, not recruiting
Anthos Investigational site 9809
Greensboro, North Carolina, 27405
- Recruiting
Anthos Investigative Site 9930
Greenville, Texas, 75401
Kamran Quddusi, kquddusi@sunbeamresearch.com
Marc Demyun
- Recruiting
Anthos Investigational site 9829
Hauppauge, New York, 11788
Daniela Tavarez, danielamtc1@icloud.com
Anna Kllogjeri, аnnagjergo@gmail.com
- Withdrawn
Anthos Investigative Site 1035
Henderson, North Carolina, 28792
- Recruiting
Anthos Investigative Site 9936
Hialeah, Florida, 33012
Ana Fernandez, afernandez@evolutionresearchcenter.com
Christian Garcia, cgarcia@evolutionresearchcenter.com
- Withdrawn
Anthos Investigative Site 1029
Holladay, Utah, 84117
- Recruiting
Anthos Investigative Site 9804
Hollywood, Florida, 33020
Ariel Soffer
- Recruiting
Anthos Investigative Site 1083
Hollywood, Florida, 33024
Ana Gonzalez, agonzalez@innovativehealthmd.com
Fernando Gonzalez Vergara
- Recruiting
Anthos Investigative Site 1087
Horsham, Pennsylvania, 19044
Samual Sharp, sam.sharp@elligodirect.com
Bruce Klugherz
- Withdrawn
Anthos Investigative Site 1069
Houston, Texas, 77002
- Recruiting
Anthos Investigative Site 1068
Houston, Texas, 77025
Siera Worthley, siera@biopharmainfo.net
Amin Karim
- Recruiting
Anthos Investigative Site 1097
Houston, Texas, 77055
Caroline People, caroline@cenaresearch.com
Asif Ali
- Recruiting
Anthos Investigative Site 9903
Houston, Texas, 77070
Dante Palacios, dpalacios@horizoncrg.com
Aditya Samal
- Withdrawn
Anthos Investigative Site 1053
Houston, Texas, 77074
- Recruiting
Anthos Investigative Site 1064
Houston, Texas, 77084
Alexis Chavez, alexis@biopharmainfo.net
Jose Madrid, jmadrid@biopharmainfo.net
- Recruiting
Anthos Investigational site 9833
Humble, Texas, 77338
Syed Safeer Zaidi, syed.zaidi@vitalheartandvein.com
Kristy Soria, ksoria@vitalheartandvein.com
- Recruiting
Anthos Investigative Site 9929
Huntington Beach, California, 92648
Maria Trisa Palmares, tpalmares@nicresearch.com
Majed Chane
- Recruiting
Anthos Investigative Site 9958
Hutchinson, Kansas, 67502
Amy Martens, amartens@innovoresearch.com
James Ruhlmann
- Recruiting
Anthos Investigative Site 9959
Imperial, California, 92251
Aaron Soto, aaron@biosolutionsresearch.com
Sohaib Tariq
- Recruiting
Anthos Investigational site 9808
Jacksonville, Florida, 32209
Hayley Cheatwood, Hayley.cheatwood@ufhealth.org
Ryen Freedman, ryen.freedman@jax.ufl.edu
- Withdrawn
Anthos Investigative Site 1008
Jacksonville, Florida, 32216
- Recruiting
Anthos Investigational site 9813
Jacksonville, Florida, 32256
Leticia Robinson, lrobinson@cnshealthcare.com
Karen Gabon, igabon@cnshealthcare.com
- Recruiting
Anthos Investigational site 9828
Jacksonville, Florida, 32256
Christopher Chan, cchan@firstcoastcardio.com
Alayina Socia, asocia@firstcoastcardio.com
- Recruiting
Anthos Investigative Site 9941
Jefferson City, Tennessee, 37760
Zachery Harkey, zachery.harkey@roviaclinical.com
Pragnesh Patel
- Recruiting
Anthos Investigative Site 1080
Kansa City, Missouri, 64151
Shari Gutto, shari.gutto@avacare.com
Scott Kuennen
- Recruiting
Anthos Investigative Site 9948
Kansas City, Missouri, 64114
Paul Bridges, hbridges@nextstageclinical.com
Alexis Simmons, asimmons@nextstageclinical.com
- Recruiting
Anthos Investigative Site 9904
Lake Mary, Florida, 32746
Kiran Penta, kiran@aorcorp.com
Vikas Verma
- Recruiting
Anthos Investigative Site 9921
Lancaster, California, 93534
Aileen Doriguzzi, adoriguzzi@chemidox.com
Anthonia Okonkwo, aokonkwo@chemidox.com
- Recruiting
Anthos Investigative Site 1023
Lanham, Maryland, 20746
Iluyomade Adeusi, iluyomade@capitolcardiology.com
Mohit Rastogi
- Recruiting
Anthos Investigational site 9819
Lansing, Michigan, 48910
Marci Roberts, Marci.roberts@mclaren.org
Katie Wrayesckilsen, katie.wrayesckilsen@mclaren.org
- Recruiting
Anthos Investigative Site 1021
Lansing, Michigan, 48912
Sandra Mitchell, sandra.mitchell@sparrow.org
John Ip
- Withdrawn
Anthos Investigative Site 9901
Laredo, Texas, 78041
- Withdrawn
Anthos Investigative Site 1036
Las Vegas, Nevada, 89119
- Recruiting
Anthos Investigative Site 9914
Las Vegas, Nevada, 89123
Seobin Kim, skim@azcrf.org
Sanjay Malhotra
- Withdrawn
Anthos Investigative Site 1001
Lenoir, North Carolina, 28638
- Withdrawn
Anthos Investigative Site 1066
Lincoln, Nebraska, 68506
- Withdrawn
Anthos Investigative Site 1052
Lithonia, Georgia, 30058
- Recruiting
Anthos Investigative Site 1078
Loma Linda, California, 92357
Agnes Lee, agnes.lee2@va.gov
Ronald Fernando
- Recruiting
Anthos Investigative Site 1077
Los Angeles, California, 90022
Yoltic Flores, flores@eastsideclinicalresearch.org
Enrique Gonzalez
- Recruiting
Anthos Investigative Site 1093
Lutz, Florida, 33558
Christian Kelbaugh, christian.kelbaugh@baycare.org
Zaruhi Babayan
- Recruiting
Anthos Investigative Site 1033
Macon, Georgia, 31201
Heather Maschenik, hmaschenik@gacri.com
Anysia Boozer, aboozer@gacri.com
- Withdrawn
Anthos Investigative Site 1010
Manassas, Virginia, 20109
- Recruiting
Anthos Investigative Site 1063
McAllen, Texas, 78503
Jessica Mata, jmata@biopharmainfo.net
Swarnalatha Kanneganti
- Recruiting
Anthos Investigative Site 1096
McKinney, Texas, 75069
Dina Sobeh, dsobeh@ndresearch.com
Ushna Naeem, unaeem@ndresearch.com
- Recruiting
Anthos Investigative Site 1079
McKinney, Texas, 75071
Kamran Quddusi, kquddusi@sunbeamresearch.com
Wael Abo-Auda
- Recruiting
Anthos Investigative Site 1056
Memphis, Tennessee, 38128
Susan Skufca, susan.skufca@careaccess.com
Joseph Weinstein
- Recruiting
Anthos Investigative Site 1098
Merrillville, Indiana, 46410
Rehan Ahmed, rahmed@indianaclinicalresearch.com
Arshad Malik
- Recruiting
Anthos Investigative Site 9933
Miami, Florida, 33145
Milene Garcia, mg.medoneclinicalresearch@outlook.com
Thierry Jacquemin
- Recruiting
Anthos Investigational site 9823
Miami Lakes, Florida, 33014
Anabel Nuez, adelanuez@inpatientresearch.com
Arazay Morales, arazayperez@inpatientresearch.com
- Withdrawn
Anthos Investigative Site 1072
Miami Lakes, Florida, 33016
- Withdrawn
Anthos Investigative Site 1014
Middletown, New York, 10941
- Recruiting
Anthos Investigative Site 1041
Mobile, Alabama, 36608
Cheryl Flock, cflock@cbflockresearch.org
John Ledoux
- Withdrawn
Anthos Investigative Site 1042
Norcross, Georgia, 30092
- Withdrawn
Anthos Investigative Site 1015
Northridge, California, 91325
- Recruiting
Anthos Investigative Site 9944
Ocala, Florida, 34471
Arleana Brown, arleana.brown@morganmmc.com
Lan Luo
- Recruiting
Anthos Investigative Site 9940
Ocala, Florida, 34474
Karen Perry, karen@ehsfamily.com
Merci Corcoran, Merci@ehsfamily.com
- Recruiting
Anthos Investigative Site 1024
Odessa, Texas, 79761
Adriana Bryan, adriana@prftx.com
Fernando Boccalandro
- Recruiting
Anthos Investigative Site 9917
Oklahoma City, Oklahoma, 73104
Aurora Vera, Aurora-Vera@ouhsc.edu
Zain Ul Abideen Asad
- Recruiting
Anthos Investigational site 9821
Orange, California, 92868
Karen Cruz, karen.cruz@damg.site
Esmeralda Anguiano, esmeralda.anguiano@damg.site
- Withdrawn
Anthos Investigative Site 1067
Ormond Beach, Florida, 32117
- Recruiting
Anthos Investigative Site 1030
Park Ridge, Illinois, 60068
Loria Awadallah, loria.awadallah@amr-clinical.com
Simon Eali, simon.eali@amrllc.com
- Recruiting
Anthis Investigational site 9811
Pensacola, Florida, 32503
Jennifer Lehman, jennifer.lehmann@bhcpns.org
Bridget Lane, bridget.lane@bhcpns.org
- Recruiting
Anthos Investigational site9830
Pensacola, Florida, 32504
Danielle struckel, danielle.struckel@ascension.org
Carole Funderburk, carole.funderburk@ascension.org
- Recruiting
Anthos Investigative Site 1099
Peoria, Arizona, 85381
Jocelyn Luque, jluque@suncitytrials.com
Kishlay Anand
- Recruiting
Anthos Investigative Site 9946
Petoskey, Michigan, 49770
Joan Morey, joan.morey@mclaren.org
Naomi Overton
- Recruiting
Anthos Investigative Site 9906
Phoenix, Arizona, 85018
Nicole Ossino, nicole@eliteclinicalstudies.com
Jason Klein
- Recruiting
Anthos Investigative Site 9950
Pinehurst, North Carolina, 28374
Bethany Wright, bwright@pinehurstmedical.com
Patrick Simpson
- Withdrawn
Anthos Investigative Site 1038
Pleasant View, Utah, 84404
- Recruiting
Anthos Investigative Site 1085
Port Arthur, Texas, 77642
Ashley Pennington, apennington@nextstageclinical.com
Paul Bridges, hbridges@nextstageclinical.com
- Active, not recruiting
Anthos Investigational site 9802
Port Orange, Florida, 32117
- Recruiting
Anthos Investigative Site 1075
Portland, Oregon, 97239
Liz Cannard, cannarde@ohsu.edu
Charles Henrikson
- Recruiting
Anthos Investigational site 9826
Puyallup, Washington, 98372
Fawna White, fawna.white@multicare.org
Trina Wesner, trina.wesner@multicare.org
- Active, not recruiting
Anthos Investigative Site 1070
Redding, California, 96001
- Recruiting
Anthos Investigative Site 9926
Redmond, Washington, 98052
Travis Maag-Brown, tmaagbrown@erahealthresearch.com
Christopher Price
- Recruiting
Anthos Investigative Site 1009
Roanoke, Virginia, 24014
Melissa Shelton, melissas@roaonkeheart.com
John Schmedtje
- Withdrawn
Anthos Investigative Site 1032
Rock Hill, South Carolina, 29732
- Recruiting
Anthos Investigative Site 9932
Rockford, Illinois, 61107
Barbara Connors, barbara.l.connors@osfhealthcare.org
Stephanie Hillis, stephanie.j.hillis@osfhealthcare.org
- Recruiting
Anthos Investigational site 9962
Rockville, Maryland, 20850
Deresa Meseret, MDeressa1@adventisthealthcare.com
Shilpa Rele, srele@adventisthealthcare.com
- Withdrawn
Anthos Investigative Site 1028
Rockville, Maryland, 20850
- Recruiting
Anthos Investigative Site 1037
Rosedale, New York, 11422
Malawika Maheswari, mmaheswari.qh@gmail.com
Olakunle Akinboboye
- Withdrawn
Anthos Investigative Site 1034
Roy, Utah, 84067
- Recruiting
Anthos Investigative Site 1026
Safety Harbor, Florida, 34695
Laura Jenkins, jenkinsl@cccheart.com
Jason Zelenka
- Recruiting
Anthos Investigative Site 1002
Saint Augustine, Florida, 32086
Keearah Galvao, keearah.galvao@eastcoastresearch.net
Cory Crain, cory.crain@eastcoastresearch.net
- Recruiting
Anthos Investigative Site 1004
Saint Augustine, Florida, 32086
Lucy Herter, lherter@encoredocs.com
Jillian Agnew, jagnew@encoredocs.com
- Recruiting
Anthos Investigational site 9969
Salisbury, Maryland, 21804
Hanna Wood, hanna.wood@tidalhealth.org
Patricia Laun, Patricia.laun@tidalhealth.org
- Recruiting
Anthos Investigative Site 1071
San Dimas, California, 91773
Syeda Naqvi, snaqvi@nariresearch.com
Yesenia Olivas, yguzman@nariresearch.com
- Withdrawn
Anthos Investigative Site 1076
Santa Ana, California, 92704
- Recruiting
Anthos Investigative Site 9938
Santa Rosa, California, 95405
Julie Rosenberg, jrosenberg@northbayclinicalresearch.com
Stephen Halpern
- Recruiting
Anthos Investigational site 9801
Sewell, New Jersey, 08080
Grace Clark, gclark@hearthousenj.com
Elizabeth Watson, ewatson@hearthousenj.com
- Recruiting
Anthos Investigative Site 9923
Sherman, Texas, 75090
Haley Payne, haley@auroraclinicalresearch.com
Nikhil Joshi
- Recruiting
Anthos Investigative Site 1043
Shreveport, Louisiana, 71103
Iris Cahn, gcahn.cvsolutions@gmail.com
Wenwu Zhang
- Recruiting
Anthos Investigational site 9963
Somerset, New Jersey, 08873
Hemangi Bandekar, hemangi.bandekar@cminj.com
Eugeny Matrossov, eugeny.matrossov@cminj.com
- Recruiting
Anthos Investigative Site 9908
South Gate, California, 90280
John Park, johnnie@charityhealth.net
Robert Azurin
- Recruiting
Anthos Investigative Site 1059
Southgate, Michigan, 48195
Natalia Gomez, ngomez@rev-research.com
Qaiser Shafiq
- Recruiting
Anthos Investigational site 9966
St Louis, Missouri, 63110
James Hermeyer, hermeyer.j@wustl.edu
Sharon Heuerman, sheuerma@dom.wustl.edu
- Recruiting
Anthos Investigational site 9825
St Louis, Missouri, 63136
Naga Kaja, nkaja@slhv.com
Paige Brown, pbrown@slhv.com
- Recruiting
Anthos Investigative Site 1012
Stamford, Connecticut, 06905
Stephanie Seredenko, sseredenko@cafconline.com
Charles Rouse
- Recruiting
Anthos Investigative Site 9951
Statesville, North Carolina, 28677
Brian Martinez, brian.martinez@piedmonthealthcare.com
Naveed Rajper
- Recruiting
Anthos Investigative Site 9935
Stony Brook, New York, 11794
Melanie Rooney, melanie.rooney@stonybrookmedicine.edu
Ryan O'Connor, ryan.o'connor@stonybrookmedicine.edu
- Withdrawn
Anthos Investigative Site 1090
Sugar Land, Texas, 77479
- Recruiting
Anthos Investigative Site 1003
Suwanee, Georgia, 30024
Charlotte Mall, charlotte@nscresearch.org
Marisol Ramos, marisol@nscresearch.org
- Recruiting
Anthos Investigative Site 1073
Tacoma, Washington, 98405
Mohsin Alagi, mohsin.universalresearch@gmail.com
Sabrina Benjamin
- Recruiting
Anthos Investigative Site 1044
Tamarac, Florida, 33321
Enrique Fernandez, enrique.fernandez@careaccess.com
Brad Lipson
- Recruiting
Anthos Investigative Site 1088
Tamarac, Florida, 33321
Diego Sanchez, dsanchez@dhnrc.com
Abel Diaz, aalonso@dhnrc.com
- Withdrawn
Anthos Investigative Site 1046
Tampa, Florida, 33625
- Recruiting
Anthos Investigative Site 9911
The Villages, Florida, 32162
Stephanie Smith, stephanie.smith@globalaes.com
Cheyenne Cashwell, cheyenne.cashwell@globalaes.com
- Withdrawn
Anthos Investigative Site 1011
Tomball, Texas, 77375
- Recruiting
Anthos Investigative Site 9953
Tucker, Georgia, 30084
Andrew Mayer, amayer@ahsmed.com
Hiwot Haile, hhaile@ahsmed.com
- Withdrawn
Anthos Investigative Site 1017
Tupelo, Mississippi, 38801
- Recruiting
Anthos Investigative Site 9916
Tyler, Texas, 75701
Amanda Baker, amanda.baker3@christushealth.org
Stanislav Weiner
- Recruiting
Anthos Investigative Site 9920
Valhalla, New York, 10595
Rajkumari Bhardwaj, rajkumari.bhardwaj@wmchealth.org
Jason Jacobson
- Recruiting
Anthos Investigative Site 9910
Victoria, Texas, 77901
Bridget Chapa, bchapa@crossroadscr.net
Katie Jordan, kjordan@crossroadscr.net
- Recruiting
Anthos Investigative Site 9949
Vienna, Virginia, 22182
Hala Ibnouf, hibnouf@delricht.com
Vijayendra Jaligam
- Recruiting
Anthos Investigative Site 9907
Vista, California, 92081
Mohammed Khalil, mohamed.khalil@bluecoastcardiology.com
Hanh Bui
- Recruiting
Anthos Investigative Site 1060
Waco, Texas, 76712
Morgan York, myork@nextstageclinical.com
Jensen Volz, jvolz@nextstageclinical.com
- Recruiting
Anthos Investigative Site 9909
Webster, Texas, 77598
Douglas Nielsen, dnielsen@clinicoretrials.com
Jay Tchamanzar, jtchamanzar@clinicoreintl.com
- Recruiting
Anthos Investigative Site 9956
West Des Moines, Iowa, 50266
Ahymad Lee, alee@innovoresearch.com
Kathleen Jones
- Recruiting
Anthos Investigational site 9803
West Monroe, Louisiana, 71291
Nina Parrot, nparrott76@gmail.com
Assad Mouhaffel
- Withdrawn
Anthos Investigative Site 9924
Westfield, New York, 14787
- Recruiting
Anthos Investigative Site 1016
Wichita, Kansas, 67207
Erina Kulitek, Erina.Kutilek@amr-clinical.com
Terry Klein
- Recruiting
Anthos Investigative Site 9952
Wilmington, North Carolina, 28401
Breanna Yopp-Chester, byoppchester@wilmingtonhealth.com
Craig McCotter
- Recruiting
Anthos Investigative Site 9925
Winfield, Illinois, 60190
Ahad Ahmad, ahad.ahmad@accellacare.com
George Nijmeh
- Recruiting
Anthos Investigative Site 1092
Wylie, Texas, 75098
Marissa Cervenka, m.cervenka@medrasaresearch.com
Tanvir Ahmad
- Recruiting
Anthos Investigative Site 9927
Yuma, Arizona, 85365
Katie Welch, katie@yumaclinicaltrials.com
Habteab Feseha
China45 sites, 39 recruiting
- Recruiting
Anthos Investigational site 1825
Beijing, Beijing Municipality, 100029
- Recruiting
Anthos Investigational Site 1826
Beijing, Beijing Municipality, 100037
- Recruiting
Anthos Investigational Site 1832
Beijing, BJ, 100191
- Recruiting
Anthos Investigational site 1831
Changchun, Jilin, 130033
- Withdrawn
Anthos Investigative Site 1818
Changchun, 130021
- Recruiting
Anthos Investigative Site 1810
Changsha, 410005
- Withdrawn
Anthos Investigative Site 1811
Changsha, 410013
- Recruiting
Anthos Investigative Site 1802
Chengdu, 610500
- Recruiting
Anthos Investigational site 1835
ChongQing, Sichuan, 400010
- Active, not recruiting
Anthos Investigational site 1839
Guangzhou, Guangdong, 510080
- Recruiting
Anthos Investigational site 1839
Guangzhou, 510080
- Recruiting
Anthos Investigative Site 1829
Guangzhou, 510515
- Recruiting
Anthos Investigative Site 1809
Haidian, 10080
- Recruiting
Anthos Investigative Site 1801
Hangzhou, 310009
- Withdrawn
Anthos Investigative Site 1808
Hangzhou, 310016
- Recruiting
Anthos Investigational site 1840
Harbin, 150001
- Recruiting
Anthos Investigational site 1838
Henan Sheng, Zhengzhou Shi, 450052
- Recruiting
Anthos Investigative Site 1816
Jinan, 250013
- Recruiting
Anthos Investigational site 1822
Jinning, Shandong, 272111
- Recruiting
Anthos Investigational site 1841
Lanzhou, Gansu, 730030
- Recruiting
Anthos Investigative Site 1804
Lianyungang, 222002
- Recruiting
Anthos Investigational site 1844
Liaoning, Liaoning, 116001
- Recruiting
Anthos Investigative Site 1814
Luoyang, 471003
- Recruiting
Anthos Investigative Site 1817
Nanchang, 330006
- Recruiting
Anthos Investigative Site 1820
Nanchang, 330009
- Recruiting
Anthos Investigational site 1842
Nanjing, JS, 210029
- Recruiting
Anthos Investigative Site 1803
Nanjing, 210008
- Recruiting
Anthos Investigative Site 1833
Nanning, Guangxi, 530021
- Withdrawn
Anthos Investigative Site 1815
Ningbo, 315016
- Recruiting
Anthos Investigational Site 1827
Shanghai, 200080
- Recruiting
Anthos Investigative Site 1834
Shantou, Guangdong, 515041
- Recruiting
Anthos Investigational site 1843
Shanxi, Shanxi, 30001
- Recruiting
Anthos Investigational site 1836
Shenzhen, Nanshan, 518057
- Recruiting
Anthos Investigational Site 1846
Shijiazhuang, Hebei, 50031
- Recruiting
Anthos Investigative Site 1819
Shijiazhuang, 50004
- Recruiting
Anthos Investigational site 1845
Tianjin, Tianjin Municipality, 300052
- Recruiting
Anthos Investigative Site 1812
Tianjin, 300121
- Recruiting
Anthos Investigational Site 1830
Wenzhou, Zhejiang, 325035
- Recruiting
Anthos Investigational site 1824
Wuchang, 430060
- Recruiting
Anthos Investigative Site 1837
Wuhan, Hubei, 430014
- Recruiting
Anthos Investigational site 1823
Xi'an, Shaanxi, 7100061
- Recruiting
Anthos Investigative Site 1821
Xi'an, Shaanxi, 710068
- Recruiting
Anthos Investigative Site 1813
Yangzhou, 225012
- Withdrawn
Anthos Investigative Site 1805
Yinchuan, 750001
- Recruiting
Anthos Investigational site 1847
Zhejiang, 325000
Brazil43 sites, 36 recruiting
- Recruiting
Anthos Investigative Site 1518
Aracaju, 49055
- Recruiting
Anthos Investigative Site 1527
Belo Horizonte, 30110-021
- Recruiting
Anthos Investigative Site 1528
Belo Horizonte, 30110
- Withdrawn
Anthos Investigative Site 1516
Belo Horizonte, 30150-242
- Recruiting
Anthos Investigative Site 1507
Belo Horizonte, 30220
- Recruiting
Anthos Investigative Site 1513
Blumenau, 89010
- Recruiting
Anthos Investigative Site 1505
Blumenau, 89020-430
- Recruiting
Anthos Investigative Site 1535
Brasília, 70200-730
- Recruiting
Anthos Investigative Site 1501
Campina Grande do Sul, 83430
- Withdrawn
Anthos Investigative Site 1503
Campinas, 13010
- Recruiting
Anthos Investigative Site 1522
Campinas, 13060
- Recruiting
Anthos Investigative Site 1520
Campo Grande, 79080-190
- Recruiting
Anthos Investigative Site 1532
Canoas, 92425
- Recruiting
Anthos Investigative Site 1526
Caxias do Sul, 95070
- Recruiting
Anthos Investigative Site 1542
Colatina, 29707
- Recruiting
Anthos Investigative Site 1540
Curitiba, 80045-395
- Recruiting
Anthos Investigative Site 1509
Curitiba, 80730
- Recruiting
Anthos Investigative Site 1525
Goiânia, 74605
- Recruiting
Anthos Investigative Site 1502
Marília, 17515-000
- Recruiting
Anthos Investigative Site 1533
Passo Fundo, 99010
- Recruiting
Anthos Investigative Site 1517
Porto Alegre, 90020-090
- Recruiting
Anthos Investigative Site 1519
Porto Alegre, 90035-903
- Recruiting
Anthos Investigative Site 1544
Porto Alegre, 90160-093
- Withdrawn
Anthos Investigative Site 1506
Porto Alegre, 90560
- Recruiting
Anthos Investigative Site 1530
Porto Alegre, 90610-000
- Withdrawn
Anthos Investigative Site 1512
Porto Alegre, 90620-001
- Recruiting
Anthos Investigative Site 1524
Porto Alegre, 90840-440
- Recruiting
Anthos Investigative Site 1508
Porto Alegre, 91350
- Recruiting
Anthos Investigative Site 1531
Recife, 52051
- Withdrawn
Anthos Investigative Site 1515
Ribeirão Preto, 14026
- Recruiting
Anthos Investigative Site 1536
Ribeirão Preto, 14051-140
- Recruiting
Anthos Investigative Site 1537
Rio de Janeiro, 20241-180
- Recruiting
Anthos Investigative Site 1510
Salvador, 40050
- Withdrawn
Anthos Investigative Site 1521
Salvador, 41810
- Recruiting
Anthos Investigative Site 1534
São Paulo, 01232
- Withdrawn
Anthos Investigative Site 1511
São Paulo, 01323-001
- Recruiting
Anthos Investigative Site 1538
São Paulo, 04012
- Recruiting
Anthos Investigative Site 1539
São Paulo, 04024-002
- Recruiting
Anthos Investigative Site 1529
São Paulo, 05403
- Recruiting
Anthos Investigative Site 1543
São Paulo, 08270-070
- Recruiting
Anthos Investigative Site 1514
Tatuí, 18270-170
- Recruiting
Anthos Investigative Site 1541
Teresina, 64001-450
- Recruiting
Anthos Investigative Site 1504
Votuporanga, 15500
India37 sites, 31 recruiting
- Withdrawn
Anthos Investigative Site 2310
Ahmedabad, 380054
- Recruiting
Anthos Investigative Site 2320
Ahmedabad, 380060
- Recruiting
Anthos Investigative Site 2330
Ajmer, 305001
- Recruiting
Anthos Investigative Site 2311
Bangalore, 560002
- Recruiting
Anthos Investigative Site 2318
Bhubaneswar, 751019
- Recruiting
Anthos Investigative Site 2303
Chandigarh, 160012
- Recruiting
Anthos Investigative Site 2324
Chennai, 600 037
- Recruiting
Anthos Investigative Site 2338
Chennai, 600017
- Recruiting
Anthos Investigative Site 2325
Chennai, 600024
- Recruiting
Anthos Investigative Site 2328
Dehradun, 248001
- Withdrawn
Anthos Investigative Site 2308
Ghaziabad, 201010
- Recruiting
Anthos Investigational Site 2342
Hyderabad, Andhra Pradesh, 500012
- Recruiting
Anthos Investigative Site 2333
Hyderabad, 500032
- Recruiting
Anthos Investigative Site 2306
Jaipur, 302005
- Recruiting
Anthos Investigative Site 2331
Jaipur, 302039
- Recruiting
Anthos Investigational site 2341
Kochi, Kerala, 682018
- Recruiting
Anthos Investigative Site 2340
Kochi, Kerala, 682040
- Withdrawn
Anthos Investigative Site 2304
Kochi, 682001
- Recruiting
Anthos Investigative Site 2314
Kolkata, 700020
- Recruiting
Anthos Investigative Site 2323
Ludhiāna, 141001
- Recruiting
Anthos Investigative Site 2326
Mangaluru, 575002
- Recruiting
Anthos Investigative Site 2329
Meerut, 250005
- Withdrawn
Anthos Investigative Site 2313
Mumbai, 400016
- Recruiting
Anthos Investigative Site 2315
Nagpur, 440001
- Recruiting
Anthos Investigative Site 2336
Nagpur, 440010
- Recruiting
Anthos Investigative Site 2316
Nagpur, 440022
- Recruiting
Anthos Investigative Site 2307
New Delhi, 110001
- Recruiting
Anthos Investigative Site 2301
New Delhi, 110002
- Withdrawn
Anthos Investigative Site 2319
New Delhi, 110029
- Recruiting
Anthos Investigative Site 2327
New Delhi, 110029
- Recruiting
Anthos Investigative Site 2322
New Delhi, 110060
- Recruiting
Anthos Investigative Site 2305
Pune, 411004
- Recruiting
Anthos Investigative Site 2317
Pune, 411028
- Recruiting
Anthos Investigational site 2344
Rudrapur, UK, 263153
- Withdrawn
Anthos Investigative Site 2309
Secunderabad, 500003
- Recruiting
Anthos Investigative Site 2312
Visakhapatnam, 530017
- Recruiting
Anthos Investigative Site 2321
Visakhapatnam, 531011
Argentina35 sites, 35 recruiting
- Recruiting
Anthos Investigational site 1400
Bahía Blanca, Buenos Aires, B8000AAK
- Recruiting
Anthos Investigational site 1443
Buenos Aires, Buenos Aires F.D., C1187AAN
- Recruiting
Anthos Investigational site 1446
Buenos Aires, Buenos Aires F.D., C1426EOB
- Recruiting
Anthos Investigative Site 1411
Buenos Aires, 1425
- Recruiting
Anthos Investigative Site 1430
Buenos Aires, 1431
- Recruiting
Anthos Investigative Site 1409
Ciudad Autónoma Buenos Aires, 1061
- Recruiting
Anthos Investigative Site 1410
Ciudad Autónoma de Buenos Aire, 1027
- Recruiting
Anthos Investigative Site 1423
Ciudad Autónoma de Buenos Aire, 1428
- Recruiting
Anthos Investigational site 1441
Ciudadela, Buenos Aires, B1702BML
- Recruiting
Anthos Investigational site 1444
Córdoba, Córdoba Province, X5000AAW
- Recruiting
Anthos Investigative Site 1407
Córdoba, 5000
- Recruiting
Anthos Investigative Site 1414
Córdoba, 5000
- Recruiting
Anthos Investigative Site 1418
Córdoba, 5000
- Recruiting
Anthos Investigative Site 1424
Córdoba, 5000
- Recruiting
Anthos Investigative Site 1427
Córdoba, 5000
- Recruiting
Anthos Investigative Site 1434
Córdoba, 5000
- Recruiting
Anthos Investigative Site 1419
Córdoba, X5000
- Recruiting
Anthos Investigative Site 1431
Córdoba, X5002AOQ
- Recruiting
Anthos Investigative Site 1429
Coronel Suárez, 7540
- Recruiting
Anthos Investigative Site 1420
Corrientes, 5700
- Recruiting
Anthos Investigational site 1438
La Plata, Buenos Aires, B1900ASM
- Recruiting
Anthos Investigative Site 1402
La Plata, 1900
- Recruiting
Anthos Investigative Site 1417
Quilmes, 1878
- Recruiting
Anthos Investigative Site 1415
Ramos Mejía, 1704
- Recruiting
Anthos Investigational site 1452
Salta, Salta Province, 4400
- Recruiting
Anthos Investigative Site 1403
Salta, 4400
- Recruiting
Anthos Investigative Site 1425
San Luis, 3400
- Recruiting
Anthos Investigative Site 1426
San Martin, 1650
- Recruiting
Anthos Investigational site 1449
San Miguel de Tucumán, Tucumán Province, 4000
- Recruiting
Anthos Investigative Site 1404
San Miguel de Tucumán, 4000
- Recruiting
Anthos Investigative Site 1435
San Miguel de Tucumán, 4000
- Recruiting
Anthos Investigational site 1451
San Miguel de Tucumán, T4000NIL
- Recruiting
Anthos Investigative Site 1436
San Nicolás, 2900
- Recruiting
Anthos Investigational site 1445
Temperley, Buenos Aires, B1834GUK
- Recruiting
Anthos Investigational site 1439
Villa María, Córdoba Province, X5900JKA
Poland34 sites, 27 recruiting
- Recruiting
Anthos Investigative Site 5029
Bialystok, 15-276
- Recruiting
Anthos Investigative Site 5022
Czeladź, 41-250
- Recruiting
Anthos Investigative Site 5033
Elblag, 82-300
- Recruiting
Anthos Investigative Site 5010
Gdynia, 81-519
- Recruiting
Anthos Investigative Site 5034
Gdynia, 81-537
- Withdrawn
Anthos Investigative Site 5003
Katowice, 40-083
- Recruiting
Anthos Investigative Site 5009
Katowice, 40-555
- Recruiting
Anthos Investigative Site 5030
Katowice, 40-635
- Recruiting
Anthos Investigative Site 5005
Katowice, 40-752
- Withdrawn
Anthos Investigative Site 5016
Krakow, 30-688
- Withdrawn
Anthos Investigative Site 5018
Krakow, 31- 501
- Recruiting
Anthos Investigative Site 5032
Legnica, 59-220
- Recruiting
Anthos Investigative Site 5021
Lodz, 91-002
- Withdrawn
Anthos Investigative Site 5012
Lodz, 91-363
- Recruiting
Anthos Investigational Site 5040
Lodz, 92-213
- Recruiting
Anthos Investigative Site 5028
Lodz, 94-046
- Recruiting
Anthos Investigative Site 5023
Lublin, 20-049
- Withdrawn
Anthos Investigative Site 5006
Lublin, 20-954
- Recruiting
Anthos Investigative Site 5039
Mielec, 39-300
- Recruiting
Anthos Investigative Site 5041
Nowa Sól, 67-100
- Withdrawn
Anthos Investigative Site 5008
Olsztyn, 10-010
- Recruiting
Anthos Investigative Site 5025
Oświęcim, 32-600
- Recruiting
Anthos Investigative Site 5002
Przemyśl, 37-700
- Recruiting
Anthos Investigative Site 5004
Rzeszów, 35-055
- Recruiting
Anthos Investigative Site 5001
Tychy, 43-100
- Recruiting
Anthos Investigative Site 5014
Warsaw, 00-215
- Recruiting
Anthos Investigative Site 5038
Warsaw, 00-710
- Recruiting
Anthos Investigative Site 5017
Warsaw, 02-097
- Recruiting
Anthos Investigative Site 5011
Warsaw, 02-637
- Recruiting
Anthos Investigative Site 5015
Warsaw, 03-291
- Recruiting
Anthos Investigative Site 5019
Wroclaw, 51-162
- Withdrawn
Anthos Investigative Site 5007
Wroclaw, 53-673
- Recruiting
Anthos Investigative Site 5024
Zabrze, 41-800
- Recruiting
Anthos Investigational site 5036
Żywiec, 34-315
Japan33 sites, 29 recruiting
- Recruiting
Anthos Investigative Site 1923
Akashi, 674-0063
- Recruiting
Anthos Investigative Site 1908
Chikushino-shi, 818-8516
- Recruiting
Anthos Investigative Site 1902
Chūōku, 103-0027
- Withdrawn
Anthos Investigative Site 1920
Funabashi-Shi, 273-8588
- Recruiting
Anthos Investigative Site 1910
Hamada-shi, 697-8511
- Recruiting
Anthos Investigative Site 1924
Hamamatsu, 432-8580
- Withdrawn
Anthos Investigative Site 1906
Himeji-Shi, 670-0836
- Recruiting
Anthos Investigative Site 1911
Imabari, 799-1502
- Recruiting
Anthos Investigative Site 1912
Isehara-Shi, 259-1193
- Recruiting
Anthos Investigative Site 1921
Kōtoku, 135-0061
- Recruiting
Anthos Investigative Site 1915
Kure-shi, 737-8505
- Recruiting
Anthos Investigative Site 1931
Matsue, 690-8509
- Recruiting
Anthos Investigative Site 1903
Matsumoto-Shi, 390-8621
- Withdrawn
Anthos Investigative Site 1907
Nagano, 380-0814
- Recruiting
Anthos Investigative Site 1929
Naha, 902-8511
- Recruiting
Anthos Investigative Site 1934
Okayama, 7008607
- Recruiting
Anthos Investigative Site 1926
Ōmihachiman, 523-0082
- Recruiting
Anthos Investigative Site 1932
Osaka, 545-8586
- Recruiting
Anthos Investigative Site 1930
Osaka, 559-0012
- Recruiting
Anthos Investigative Site 1922
Sapporo, 063-0005
- Recruiting
Anthos Investigative Site 1904
Sendai, 983-8520
- Withdrawn
Anthos Investigative Site 1913
Shimonoseki-shi, 752-8510
- Recruiting
Anthos Investigative Site 1914
Tachikawa-shi, 190-0014
- Recruiting
Anthos Investigative Site 1909
Tochigi, 321-0293
- Recruiting
Anthos Investigative Site 1925
Tokushima, 770-8503
- Recruiting
Anthos Investigative Site 1933
Tokyo, 176-8530
- Recruiting
Anthos Investigative Site 1927
Tōon, 791-0281
- Recruiting
Anthos Investigative Site 1928
Toyama, 930-0194
- Recruiting
Anthos Investigative Site 1901
Urayasu, 279-0001
- Recruiting
Anthos Investigative Site 1917
Uwajima-Shi, 798-8510
- Recruiting
Anthos Investigative Site 1918
Yokohama, 232-0024
- Recruiting
Anthos Investigative Site 1919
Yokohama, 236-0037
- Recruiting
Anthos Investigative Site 1916
Yokohama, 245-8575
Bulgaria31 sites, 28 recruiting
- Recruiting
Anthos Investigative Site 6014
Blagoevgrad, 2700
- Recruiting
Anthos Investigative Site 6026
Burgas, 8000
- Recruiting
Anthos Investigative Site 6019
Gabrovo, 5300
- Recruiting
Anthos Investigative Site 6032
Haskovo, 6300
- Recruiting
Anthos Investigative Site 6018
Haskovo, 6304
- Withdrawn
Anthos Investigative Site 6013
Panagyurishte, 4500
- Recruiting
Anthos Investigative Site 6025
Pazardzhik, 4400
- Recruiting
Anthos Investigative Site 6006
Pleven, 5804
- Recruiting
Anthos Investigative Site 6003
Pleven, 5808
- Recruiting
Anthos Investigative Site 6007
Plovdiv, 4000
- Recruiting
Anthos Investigative Site 6008
Plovdiv, 4000
- Recruiting
Anthos Investigative Site 6009
Plovdiv, 4000
- Recruiting
Anthos Investigative Site 6004
Plovdiv, 4003
- Recruiting
Anthos Investigative Site 6021
Plovdiv, 4003
- Recruiting
Anthos Investigative Site 6031
Rousse, 7013
- Recruiting
Anthos Investigative Site 6027
Sliven, 8800
- Recruiting
Anthos Investigative Site 6034
Sliven, 8800
- Recruiting
Anthos Investigative Site 6022
Smolyan, 4700
- Recruiting
Anthos Investigative Site 6030
Sofia, 1142
- Recruiting
Anthos Investigative Site 6028
Sofia, 1202
- Recruiting
Anthos Investigative Site 6029
Sofia, 1233
- Recruiting
Anthos Investigative Site 6024
Sofia, 1404
- Recruiting
Anthos Investigative Site 6023
Sofia, 1407
- Recruiting
Anthos Investigative Site 6010
Sofia, 1431
- Recruiting
Anthos Investigative Site 6015
Sofia, 1431
- Recruiting
Anthos Investigative Site 6020
Sofia, 1527
- Recruiting
Anthos Investigative Site 6001
Sofia, 1606
- Recruiting
Anthos Investigative Site 6017
Sofia, 1606
- Withdrawn
Anthos Investigative Site 6012
Sofia, 1618
- Recruiting
Anthos Investigative Site 6002
Sofia, 1709
- Withdrawn
Anthos Investigative Site 6011
Stara Zagora, 6000
Italy29 sites, 22 recruiting
- Recruiting
Anthos Investigative Site 8016
Ancona, 60129
- Withdrawn
Anthos Investigative Site 8003
Bologna, 40138
- Recruiting
Anthos Investigative Site 8015
Brescia, 25123
- Recruiting
Anthos Investigative Site 8020
Cagliari, 9121
- Recruiting
Anthos Investigative Site 8019
Caserta, 81100
- Withdrawn
Anthos Investigative Site 8008
Catanzaro, 88100
- Withdrawn
Anthos Investigative Site 8021
Cinisello Balsamo, 20092
- Recruiting
Anthos Investigative Site 8024
Florence, 50134
- Recruiting
Anthos Investigative Site 8013
Lecco, 23900
- Withdrawn
Anthos Investigative Site 8007
Milan, 20138
- Recruiting
Anthos Investigative Site 8001
Milan, 20162
- Recruiting
Anthos Investigative Site 8026
Naples, 80100
- Recruiting
Anthos Investigative Site 8023
Naples, 80131
- Withdrawn
Anthos Investigative Site 8017
Palermo, 90127
- Recruiting
Anthos Investigative Site 8025
Pisa, 56124
- Recruiting
Anthos Investigative Site 8029
Pisa, 56126
- Recruiting
Anthos Investigative Site 8031
Ravenna, 48182
- Recruiting
Anthos Investigative Site 8030
Rimini, 47923
- Recruiting
Anthos Investigative Site 8028
Rivoli, 10098
- Recruiting
Anthos Investigative Site 8010
Roma, 00152
- Withdrawn
Anthos Investigative Site 8011
Roma, 00163
- Withdrawn
Anthos Investigative Site 8002
Roma, 161
- Recruiting
Anthos Investigative Site 8022
Rome, 00168
- Recruiting
Anthos Investigational Site 8027
Rome, 189
- Recruiting
Anthos Investigative Site 8004
Saronno, 21052
- Recruiting
Anthos Investigative Site 8005
Sesto San Giovanni, 20099
- Recruiting
Anthos Investigative Site 8014
Torino, 10128
- Recruiting
Anthos Investigative Site 8006
Varese, 21100
- Recruiting
Anthos Investigative Site 8009
Vittoria, 97019
United Kingdom29 sites, 23 recruiting
- Recruiting
Anthos Investigational site 1329
Blackpool, Lancanshire, FY3 8NR
- Recruiting
Anthos Investigational site 1327
Bollington, Cheshire, SK105JH
- Recruiting
Anthos Investigational site 1328
Brierley Hill, West Midlands, DY5 1RU
- Withdrawn
Anthos Investigative Site 1303
Corby, NN17 2UR
- Withdrawn
Anthos Investigative Site 1313
Glasgow, G20 0XA
- Recruiting
Anthos Investigative Site 1320
Glasgow, G51 4TF
- Recruiting
Anthos Investigative Site 1315
Hayle, TR27 5DT
- Recruiting
Anthos Investigative Site 1311
High Wycombe, HP11 2TT
- Recruiting
Anthos Investigative Site 1301
Isleworth, TW7 6AF
- Recruiting
Anthos Investigative Site 1316
Kings Lynn, PE30 4ET
- Recruiting
Anthos Investigative Site 1324
Lancaster, LA1 4ZP
- Withdrawn
Anthos Investigative Site 1322
Larbert, FK5 4WR
- Recruiting
Anthos Investigative Site 1309
Leeds, LS1 3EX
- Recruiting
Anthos Investigative Site 1325
Liverpool, L14 3PE
- Withdrawn
Anthos Investigative Site 1314
London, IG1 4HP
- Recruiting
Anthos Investigative Site 1319
London, NW1 5DH
- Recruiting
Anthos Investigative Site 1326
London, NW10 2PT
- Recruiting
Anthos Investigative Site 1308
London, SW3 6NP
- Recruiting
Anthos Investigative Site 1323
Luton, LU4 0DZ
- Recruiting
Anthos Investigative Site 1312
Manchester, M27 8FF
- Withdrawn
Anthos Investigative Site 1307
Newcastle upon Tyne, NE7 7DN
- Recruiting
Anthos Investigative Site 1318
Norwich, NR2 2TJ
- Recruiting
Anthos Investigational site 1330
Oxford, OX3 9JA
- Recruiting
Anthos Investigative Site 1305
Peterborough, PE3 9GZ
- Recruiting
Anthos Investigative Site 1321
Romford, RM7 0AG
- Recruiting
Anthos Investigative Site 1302
Stevenage, SG1 4AB
- Recruiting
Anthos Investigative Site 1310
Stockton-on-Tees, TS19 8PE
- Recruiting
Anthos Investigative Site 1317
Stoke-on-Trent, ST4 6QG
- Withdrawn
Anthos Investigative Site 1306
Taunton, TA1 5DA
Canada24 sites, 21 recruiting
- Recruiting
Anthos Investigative Site 2016
Abbotsford British Columbia, V2S 0C2
- Withdrawn
Anthos Investigative Site 2019
Brampton, L6R 3J7
- Recruiting
Anthos Investigative Site 2003
Cambridge, Ontario, N1R 7R1
- Recruiting
Anthos Investigative Site 2007
Chicoutimi, Quebec, G7H 5H6
- Recruiting
Anthos Investigative Site 2015
Edmonton, T6G 2G3
- Recruiting
Anthos Investigative Site 2018
Greenfield Park, J4V 2H1
- Recruiting
Anthos Investigative Site 2005
Halifax, B3H 3A7
- Recruiting
Anthos Investigative Site 2025
Hamilton, L8L 2X2
- Recruiting
Anthos Investigative Site 2026
Hamilton, L8N 4A6
- Recruiting
Anthos Investigational site 2029
London, Ontario, N6A 5A5
- Recruiting
Anthos Investigative Site 2028
Markham, L3P7P3
- Recruiting
Anthos Investigative Site 2012
Mira Road, Nova Scotia, B1M DA1
- Recruiting
Anthos Investigative Site 2014
Montreal, H1T 1C8
- Withdrawn
Anthos Investigative Site 2004
New Westminster, V3L 3W4
- Recruiting
Anthos Investigative Site 2021
North Vancouver, V7M 2H4
- Recruiting
Anthos Investigative Site 2002
Québec, G1R 2J6
- Recruiting
Anthos Investigative Site 2024
Saint Catharines, L2P 2W8
- Withdrawn
Anthos Investigative Site 2006
Saint-Jérôme, J7Z 5T3
- Recruiting
Anthos Investigative Site 2010
Sherbrooke, Quebec, J1H 5N4
- Recruiting
Anthos Investigative Site 2027
Terrebonne, J6V 2H2
- Recruiting
Anthos Investigative Site 2022
Thunder Bay, P7B 5N3
- Recruiting
Anthos Investigative Site 2017
Toronto, M4N 3M5
- Recruiting
Anthos Investigative Site 2020
Toronto, M4N 3M5
- Recruiting
Anthos Investigative Site 2023
Toronto, M5S 1B2
Romania23 sites, 15 recruiting
- Withdrawn
Anthos Investigative Site 9022
Baloteşti, 077015
- Withdrawn
Anthos Investigative Site 9001
Brăila, 810325
- Recruiting
Anthos Investigative Site 9028
Brasov, 500102
- Recruiting
Anthos Investigative Site 9023
Bucharest, 12296
- Withdrawn
Anthos Investigative Site 9019
Bucharest, 14461
- Recruiting
Anthos Investigative Site 9031
Bucharest, 21337
- Recruiting
Anthos Investigational Site 9029
Bucharest, 22328
- Recruiting
Anthos Investigative Site 9024
Cluj-Napoca, 400139
- Recruiting
Anthos Investigative Site 9017
Craiova, 200513
- Recruiting
Anthos Investigative Site 9006
Craiova, 200642
- Recruiting
Anthos Investigative Site 9010
Oradea, 410169
- Recruiting
Anthos Investigative Site 9025
Piteşti, 110003
- Recruiting
Anthos Investigative Site 9014
Piteşti, 110424
- Withdrawn
Anthos Investigative Site 9012
Satu Mare, 440055
- Withdrawn
Anthos Investigative Site 9003
Târgu Mureş, 540124
- Recruiting
Anthos Investigative Site 9004
Târgu Mureş, 540136
- Recruiting
Anthos Investigative Site 9016
Târgu Mureş, 540136
- Recruiting
Anthos Investigative Site 9021
Târgu Mureş, 540143
- Recruiting
Anthos Investigative Site 9007
Timișoara, 300079
- Withdrawn
Anthos Investigative Site 9005
Timișoara, 300310
- Withdrawn
Anthos Investigative Site 9018
Timișoara, 300310
- Recruiting
Anthos Investigative Site 9013
Timișoara, 300362
- Withdrawn
Anthos Investigative Site 9008
Timișoara, 300480
Spain23 sites, 14 recruiting
- Withdrawn
Anthos Investigative Site 1108
A Coruña, 15006
- Withdrawn
Anthos Investigative Site 1116
Almería, 04009
- Recruiting
Anthos Investigative Site 1121
Barcelona, 8035
- Recruiting
Anthos Investigative Site 1124
Barcelona, 8041
- Withdrawn
Anthos Investigative Site 1120
Barcelona, 8902
- Recruiting
Anthos Investigative Site 1109
Cabra, 14940
- Recruiting
Anthos Investigative Site 1103
Granada, 18014
- Recruiting
Anthos Investigative Site 1111
Jaén, 23007
- Recruiting
Anthos Investigative Site 1118
León, 24071
- Recruiting
Anthos Investigative Site 1104
Madrid, 28003
- Recruiting
Anthos Investigative Site 1117
Madrid, 28010
- Withdrawn
Anthos Investigative Site 1106
Madrid, 28035
- Withdrawn
Anthos Investigative Site 1113
Madrid, 28046
- Withdrawn
Anthos Investigative Site 1105
Málaga, 29010
- Recruiting
Anthos Investigative Site 1110
Murcia, 30120
- Withdrawn
Anthos Investigative Site 1115
Oviedo, 33006
- Withdrawn
Anthos Investigative Site 1123
Sabadell, 8208
- Recruiting
Anthos Investigative Site 1107
Santiago de Compostela, 15706
- Recruiting
Anthos Investigative Site 1102
Seville, 41009
- Recruiting
Anthos Investigative Site 1122
Seville, 41013
- Withdrawn
Anthos Investigative Site 1112
Terrassa, 08221
- Recruiting
Anthos Investigative Site 1101
Valencia, 46010
- Recruiting
Anthos Investigative Site 1119
Vigo, 36213
Mexico17 sites, 15 recruiting
- Recruiting
Anthos Investigative Site 1701
Aguascalientes, 20230
- Withdrawn
Anthos Investigative Site 1707
Aguascalientes, 20230
- Recruiting
Anthos Investigative Site 1713
Aguascalientes, 20230
- Recruiting
Anthos Investigative Site 1721
Chihuahua City, 31200
- Recruiting
Anthos Investigative Site 1703
Culiacán, 80230
- Recruiting
Anthos Investigative Site 1715
Guadalajara, 44670
- Recruiting
Anthos Investigative Site 1711
Guerrero, 39901
- Recruiting
Anthos Investigative Site 1712
Mexico City, 03100
- Recruiting
Anthos Investigative Site 1704
Monterrey, 64000
- Recruiting
Anthos Investigative Site 1705
Monterrey, 64718
- Recruiting
Anthos Investigative Site 1719
Monterrey, 64718
- Withdrawn
Anthos Investigative Site 1702
Querétaro, 76000
- Recruiting
Anthos Investigative Site 1718
San Luis Potosí City, 78200
- Recruiting
Anthos Investigative Site 1716
Tlalpan, 14080
- Recruiting
Anthos Investigative Site 1706
Veracruz, 91900
- Recruiting
Anthos Investigative Site 1708
Veracruz, 91900
- Recruiting
Anthos Investigative Site 1709
Xalapa, 91193
South Korea17 sites, 17 recruiting
- Recruiting
Anthos Investigative Site 2609
Anyang-si, 14068
- Recruiting
Anthos Investigative Site 2610
Busan, 47392
- Recruiting
Anthos Investigative Site 2606
Busan, 49241
- Recruiting
Anthos Investigative Site 2614
Daegu, 42472
- Recruiting
Anthos Investigative Site 2613
Daejeon, 35015
- Recruiting
Anthos Investigative Site 2615
Goyang-si, 10380
- Recruiting
Anthos Investigative Site 2602
Gwangju, 61469
- Recruiting
Anthos Investigative Site 2611
Gyeonggi-do, 13496
- Recruiting
Anthos Investigative Site 2604
Seongnam-si, 13620
- Recruiting
Anthos Investigative Site 2608
Seoul, 2841
- Recruiting
Anthos Investigative Site 2617
Seoul, 3080
- Recruiting
Anthos Investigative Site 2603
Seoul, 3312
- Recruiting
Anthos Investigative Site 2601
Seoul, 3722
- Recruiting
Anthos Investigative Site 2612
Seoul, 5505
- Recruiting
Anthos Investigative Site 2616
Seoul, 8308
- Recruiting
Anthos Investigative Site 2607
Ulsan, 44033
- Recruiting
Anthos Investigative Site 2605
Yongin-si, 16995
Hungary16 sites, 9 recruiting
- Recruiting
Anthos Investigative Site 4002
Békéscsaba, 5600
- Recruiting
Anthos Investigational site 4019
Budapest, Budapest, 1222
- Withdrawn
Anthos Investigative Site 4015
Budapest, 1021
- Withdrawn
Anthos Investigative Site 4006
Budapest, 1036
- Recruiting
Anthos Investigative Site 4009
Budapest, 1088
- Recruiting
Anthos Investigative Site 4018
Budapest, 1132
- Recruiting
Anthos Investigative Site 4014
Budapest, 1134
- Recruiting
Anthos Investigational site 4019
Budapest, 1222
- Withdrawn
Anthos Investigative Site 4011
Gyöngyös, 3200
- Withdrawn
Anthos Investigative Site 4012
Kaposvár, 7400
- Recruiting
Anthos Investigative Site 4007
Kistarcsa, 2143
- Withdrawn
Anthos Investigative Site 4005
Nyíregyháza, 4400
- Withdrawn
Anthos Investigative Site 4010
Pécs, 7623
- Recruiting
Anthos Investigative Site 4017
Szeged, 6725
- Recruiting
Anthos Investigative Site 4016
Veszprém, 8200
- Withdrawn
Anthos Investigative Site 4008
Zalaegerszeg, 8900
Turkey (Türkiye)15 sites, 15 recruiting
- Recruiting
Anthos Invesitgational site 3211
Adana, Adana, 1330
- Recruiting
Anthos Investigational site 3215
Adana, Adana, 4522
- Recruiting
Anthos Investigative Site 3203
Ankara, 06520
- Recruiting
Anthos Investigative Site 3207
Antalya, 7070
- Recruiting
Anthos Investigative Site 3201
Bursa, 16310
- Recruiting
Anthos Investigative Site 3208
Diyarbakır, 21070
- Recruiting
Anthos Investigational site 3210
Istanbul, Istanbul, 34010
- Recruiting
Anthos Investigative Site 3209
Istanbul, 34835
- Recruiting
Anthos Investigational site 3205
Izmir, İzmir, 35340
- Recruiting
Anthos Investigative Site 3202
Kayseri, 38039
- Recruiting
Anthos Investigational site 3212
Kocaeli, 41060
- Recruiting
Anthos Investigational site 3216
Kütahya, 43100
- Recruiting
Anthos Investigative Site 3206
Mersin, 33110
- Recruiting
Anthos Investigational site 3213
Pendik, Istanbul, 34899
- Recruiting
Anthos Investigative Site 3204
Samsun, 55090
Colombia14 sites, 14 recruiting
- Recruiting
Anthos Investigative Site 2503
Armenia, QUI, 630004
- Recruiting
Anthos Investigative Site 2513
Barranquilla, 80012
- Recruiting
Anthos Investigative Site 2504
Barranquilla, 80020
- Recruiting
Anthos Investigative Site 2512
Barranquilla, 80020
- Recruiting
Anthos Investigative Site 2511
Cali, 760032
- Recruiting
Anthos Investigative Site 2507
Cartagena, 130010
- Recruiting
Anthos Investigative Site 2506
Floridablanca, 681004
- Recruiting
Anthos Investigative Site 2501
Manizales, Caldas Department, 170004
- Recruiting
Anthos Investigational site 2509
Medellín, Antioquia, 50034
- Recruiting
Anthos Investigative Site 2508
Medellín, 50015
- Recruiting
Anthos Investigative Site 2502
Pereira, 660003
- Recruiting
Anthos Investigative Site 2510
Piedecuesta, 681017
- Recruiting
Anthos Investigative Site 2505
Soledad, 083001
- Recruiting
Anthos Investigational site 2514
Suba, Bogota D.C., 111121
Greece14 sites, 13 recruiting
- Recruiting
Anthos Investigative Site 2714
Athens, 11521
- Recruiting
Anthos Investigative Site 2711
Athens, 14233
- Recruiting
Anthos Investigative Site 2704
Athens, 15669
- Recruiting
Anthos Investigative Site 2702
Cholargós, 155 62
- Recruiting
Anthos Investigative Site 2705
Glyfada, 166 75
- Active, not recruiting
Anthos Investigational site 2713
Haidari, WA, 12462
- Recruiting
Anthos Investigational site 2707
Ioannina, 45221
- Recruiting
Anthos Investigative Site 2706
Larissa, 41110
- Recruiting
Anthos Investigational site 2703
Magoula, 19018
- Recruiting
Anthos Investigative Site 2712
Marousi, 12462
- Recruiting
Anthos Investigative Site 2715
Rio, 26504
- Recruiting
Anthos Investigative Site 2709
Thessaloniki, 546 36
- Recruiting
Anthos Investigative Site 2708
Thessaloniki, 54636
- Recruiting
Anthos Investigative Site 2710
Voula, 166 73
Israel13 sites, 11 recruiting
- Recruiting
Anthos Investigative Site 1210
Afula, 18101
- Recruiting
Anthos Investigative Site 1205
Ashkelon, 7827804
- Recruiting
Anthos Investigative Site 1213
Beersheba, 8489507
- Recruiting
Anthos Investigative Site 1206
Hadera, 38100
- Withdrawn
Anthos Investigative Site 1211
Haifa, 31048
- Withdrawn
Anthos Investigative Site 1201
Haifa, 3109601
- Recruiting
Anthos Investigative Site 1209
Holon, 58100
- Recruiting
Anthos Investigative Site 1212
Jerusalem, 91999
- Recruiting
Anthos Investigative Site 1204
Kfar Saba, 44281
- Recruiting
Anthos Investigative Site 1202
Nahariya, 22100
- Recruiting
Anthos Investigative Site 1207
Petah Tikva, 49100
- Recruiting
Anthos Investigative Site 1203
Rehovot, 7610001
- Recruiting
Anthos Investigative Site 1208
Safed, 13110
Malaysia13 sites, 13 recruiting
- Recruiting
Anthos Investigative Site 3513
Alor Star, 5460
- Recruiting
Anthos Investigative Site 3501
Kajang, 43000
- Recruiting
Anthos Investigative Site 3505
Kuala Lumpur, 59100
- Recruiting
Anthos Investigative Site 3508
Kuantan, 25100
- Recruiting
Anthos Investigative Site 3511
Kuantan, 25200
- Recruiting
Anthos Investigative Site 3510
Kuching, 93586
- Recruiting
Anthos Investigative Site 3503
Kuching, 94300
- Recruiting
Anthos Investigative Site 3506
Miri, 98000
- Recruiting
Anthos Investigative Site 3509
Putrajaya, 62150
- Recruiting
Anthos Investigative Site 3502
Seberang Jaya, 13700
- Recruiting
Anthos Investigative Site 3507
Seremban, 70300
- Recruiting
Anthos Investigative Site 3512
Sibu, 96000
- Recruiting
Anthos Investigative Site 3504
Sungai Buloh, 47000
Serbia12 sites, 12 recruiting
- Recruiting
Anthos Investigative Site 2901
Belgrade, 11000
- Recruiting
Anthos Investigative Site 2903
Belgrade, 11000
- Recruiting
Anthos Investigative Site 2905
Belgrade, 11000
- Recruiting
Anthos Investigative Site 2908
Belgrade, 11000
- Recruiting
Anthos Investigative Site 2911
Belgrade, 11000
- Recruiting
Anthos Investigative Site 2909
Belgrade, 11080
- Recruiting
Anthos Investigative Site 2904
Kragujevac, 34000
- Recruiting
Anthos Investigative Site 2912
Niš, 18000
- Recruiting
Anthos Investigative Site 2910
Novi Pazar, 36300
- Recruiting
Anthos Investigative Site 2906
Smederevo, 11300
- Recruiting
Anthos Investigative Site 2902
Užice, 31000
- Recruiting
Anthos Investigative Site 2907
Zaječar, 19000
Germany11 sites, 3 recruiting
- Withdrawn
Anthos Investigative Site 7006
Altenburg, 4600
- Withdrawn
Anthos Investigative Site 7014
Berlin, 10117
- Withdrawn
Anthos Investigative Site 7004
Dresden, 01069
- Withdrawn
Anthos Investigative Site 7012
Hamburg, 20246
- Withdrawn
Anthos Investigative Site 7003
Hamburg, 20253
- Withdrawn
Anthos Investigative Site 7013
Hanover, 30159
- Withdrawn
Anthos Investigative Site 7009
Ludwigshafen, 67063
- Recruiting
Anthos Investigational site 7018
Ludwigshafen, 67067
- Recruiting
Anthos Investigative Site 7002
Markkleeberg, 04416
- Recruiting
Anthos Investigative Site 7007
Paderborn, 33098
- Withdrawn
Anthos Investigative Site 7001
Schwerin, 19055
Latvia11 sites, 7 recruiting
- Withdrawn
Anthos Investigative Site 2103
Baldone, LV-2125
- Withdrawn
Anthos Investigative Site 2109
Balvi, LV-4501
- Recruiting
Anthos Investigative Site 2107
Daugavpils, LV-5417
- Withdrawn
Anthos Investigative Site 2108
Limbaži, LV-4001
- Recruiting
Anthos Investigative Site 2110
Riga, 1001
- Recruiting
Anthos Investigative Site 2101
Riga, 1024
- Recruiting
Anthos Investigative Site 2105
Riga, LV-1002
- Recruiting
Anthos Investigative Site 2102
Riga, LV-1038
- Recruiting
Anthos Investigative Site 2111
Sigulda, LV-2150
- Withdrawn
Anthos Investigative Site 2104
Valmiera, 4201
- Recruiting
Anthos Investigative Site 2106
Valmiera, 4201
South Africa11 sites, 9 recruiting
- Recruiting
Anthos Investigative Site 2411
Bellville, 7530
- Recruiting
Anthos Investigative Site 2409
Benoni, 1501
- Recruiting
Anthos Investigative Site 2417
Cape Town, 7580
- Recruiting
Anthos Investigational site 2408
Centurion, 0157
- Recruiting
Anthos Investigative Site 2408
Centurion, 0157
- Recruiting
Anthos Investigative Site 2412
Durban, 4001
- Recruiting
Anthos Investigative Site 2416
Johannesburg, 2182
- Recruiting
Anthos Investigative Site 2402
Pretoria, 0181
- Withdrawn
Anthos Investigative Site 2414
Pretoria, 0184
- Withdrawn
Anthos Investigative Site 2415
Somerset West, 7130
- Recruiting
Anthos Investigative Site 2405
Tongaat, 4400
Chile10 sites, 7 recruiting
- Recruiting
Anthos Investigative Site 1605
Concepción, 4030000
- Recruiting
Anthos Investigative Site 1606
Independencia, 8380465
- Withdrawn
Anthos Investigative Site 1604
Providencia, 7500739
- Recruiting
Anthos Investigative Site 1607
San Bernardo, 8050000
- Withdrawn
Anthos Investigative Site 1609
San Miguel, 8900000
- Recruiting
Anthos Investigative Site 1608
Santiago, 8320000
- Recruiting
Anthos Investigative Site 1610
Talcahuano, 4270918
- Withdrawn
Anthos Investigative Site 1603
Temuco, 4780000
- Recruiting
Anthos Investigative Site 1602
Temuco, 4810345
- Recruiting
Anthos Investigative Site 1601
Viña del Mar, 2520997
Czechia10 sites, 8 recruiting
- Recruiting
Anthos Investigative Site 3002
Brandýs nad Labem, 250 01
- Recruiting
Anthos Investigative Site 3006
Liberec, 460 01
- Recruiting
Anthos Investigative Site 3007
Ostrava - Poruba, 70868
- Recruiting
Anthos Investigative Site 3001
Poděbrady, 29001
- Withdrawn
Anthos Investigative Site 3005
Prague, 100 34
- Recruiting
Anthos Investigative Site 3004
Prague, 128 00
- Withdrawn
Anthos Investigative Site 3003
Prague, 128 08
- Recruiting
Anthos Investigative Site 3010
Prague, 150 06
- Recruiting
Anthos Investigative Site 3009
Trutnov, 541 01
- Recruiting
Anthos Investigative Site 3011
Ústí nad Labem, 400 11
Philippines10 sites, 10 recruiting
- Recruiting
Anthos Investigative Site 3603
Angeles City, 2009
- Recruiting
Anthos Investigational site 3602
City of Muntinlupa, 1780
- Recruiting
Anthos Investigative Site 3601
Davao City, 8000
- Recruiting
Anthos Investigative Site 3608
Iloilo City, 5000
- Recruiting
Anthos Investigative Site 3610
Lahug, 6000
- Recruiting
Anthos Investigative Site 3604
Lipa City, 4217
- Recruiting
Anthos Investigational Site 3605
Manila, Manila, 1000
- Recruiting
Anthos Investigational site 3609
Pasig, 1600
- Recruiting
Anthos Investigational site 3607
Quezon City, 1109
- Recruiting
Anthos Investigational site 3606
San Juan City, 1502
Croatia9 sites, 8 recruiting
- Recruiting
Anthos Investigative Site 3102
Krapinske Toplice, 49217
- Recruiting
Anthos Investigative Site 3108
Osijek, 31000
- Recruiting
Anthos Investigative Site 3107
Rijeka, 51000
- Recruiting
Anthos Investigative Site 3111
Zabok, 49210
- Recruiting
Anthos Investigative Site 3109
Zadar, 23000
- Recruiting
Anthos Investigative Site 3101
Zagreb, 10000
- Withdrawn
Anthos Investigative Site 3103
Zagreb, 10000
- Recruiting
Anthos Investigative Site 3104
Zagreb, 10000
- Recruiting
Anthos Investigative Site 3110
Zagreb, 10000
Slovakia7 sites, 6 recruiting
- Recruiting
Anthos Investigative Site 2801
Bardejov, 085 01
- Withdrawn
Anthos Investigative Site 2807
Bratislava, 821 07
- Recruiting
Anthos Investigative Site 2805
Košice, 040 01
- Recruiting
Anthos Investigative Site 2806
Lučenec, 984 01
- Recruiting
Anthos Investigative Site 2809
Nové Zámky, 94002
- Recruiting
Anthos Investigative Site 2802
Piešťany, 921 01
- Recruiting
Anthos Investigative Site 2804
Žilina, 010 01
Peru6 sites, 6 recruiting
- Recruiting
Anthos Investigative Site 3706
Piura, 20001
- Recruiting
Anthos Investigative Site 3708
San Borja, 15036
- Recruiting
Anthos Investigational site 3704
San Isidro, Lima region, L-27
- Recruiting
Anthos Investigative Site 3703
San Isidro, Lima region, LIMA 33
- Recruiting
Anthos Investigational site 3709
San Martín de Porres, Lima region, 15102
- Recruiting
Anthos Investigational site 3705
San Miguel, Lima region, 15088
Sweden4 sites, 4 recruiting
- Recruiting
Anthos Investigative Site 3303
Danderyd, 182 88
- Recruiting
Anthos Investigative Site 3302
Örebro, 70185
- Recruiting
Anthos Investigative Site 3301
Stockholm, 117 27
- Recruiting
Anthos Investigative Site 3303
Stockholm, 18288
Estonia3 sites, 1 recruiting
- Withdrawn
Anthos Investigative Site 2203
Tallinn, 10138
- Withdrawn
Anthos Investigative Site 2202
Tallinn, 10617
- Recruiting
Anthos Investigative Site 2201
Tallinn, 13419
Finland3 sites, 2 recruiting
- Active, not recruiting
Anthos Investigational site 3402
Helsinki, Uusimaa, 29
- Recruiting
Anthos Investigative Site 3401
Joensuu, 80210
- Recruiting
Anthos Investigative Site 3403
Turku, 20520
Puerto Rico3 sites, 3 recruiting
- Recruiting
Anthos Investigational Site 3803
Humacao, Puerto Rico, 791
- Recruiting
Anthos Investigational site 3802
San Juan, San Juan, 00921-3201
- Recruiting
Anthos Investigational site 3801
San Juan, San Juan, 907
About this study
Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
Read the detailed description
Patients enrolled in the study are randomized in a 1:1 ratio to receive abelacimab 150 mg SC or matching placebo once monthly. The study is comprised of 3 periods: 1) screening period of up to 60 days, 2) an event-driven, double-blind treatment period (abelacimab 150 mg SC or matching placebo) completed after at least 111 patients have experienced an adjudicated primary endpoint event, and 3) EoT visit in core part followed by either (i) a 30-day follow-up period (EoS for core part) OR (ii) an optional OLE beginning at the EoT visit for eligible patients to receive open-label abelacimab treatment. The optional extension will only be offered to patients following regulatory and ethics approval in participating countries.
- Conditions
- Atrial Fibrillation (AF)
- Being tested
- Abelacimab, Placebo
- Keywords
- abelacimab, randomized, placebo-controlled, double-blind, endpoint evaluation, atrial fibrillation
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AbelacimabBiological
Also called MAA868
Abelacimab provided as liquid in vial (150 mg/mL)
PlaceboDrug
Dosage Formulation: Liquid (in vial)
Dose Strength: Placebo to Abelacimab
| Study group | Role | What they receive |
|---|---|---|
| Abelacimab (MAA868) | Experimental | Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly. Receives: Biological: Abelacimab |
| Placebo | Placebo comparator | Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Efficacy: Time to first event of ischemic stroke or systemic embolism (SE)
Undetermined strokes will be counted as ischemic strokes
Measured: Up to 30 months
Safety: Time to first occurrence of Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding
Measured: Up to 30 months
Secondary outcomes (5)
Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), or acute limb ischemia
Abelacimab versus placebo with regard to the composite of ischemic stroke, SE, MI, VTE, or acute limb ischemia
Measured: Up to 30 months
Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), or Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding event
Measured: Up to 30 months
Efficacy: Cardiovascular (CV) mortality
Measured: Up to 30 months
Efficacy: All-cause mortality
Measured: Up to 30 months
Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), acute limb ischemia, or International Society on Thrombosis and Haemostasis (ISTH) major bleeding
Abelacimab versus placebo with regard to net clinical outcome defined as the composite of ischemic stroke, SE, MI, VTE, acute limb ischemia, or International Society on Thrombosis and Haemostasis (ISTH) major bleeding
Measured: Up to 30 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2023
- Study start27 Dec 2022
- Primary completion30 Dec 2027 (estimated)
- Study completion30 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Atrial Fibrillation (AF)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 2,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Anthos Therapeutics, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Novartis Pharmaceuticals
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05712200
- Sponsor's protocol ID
- ANT-010
- Other IDs
- 2023-503224-66-00, CMAA868A2302, 2023
- Acronym
- LILAC-TIMI 76
- Status last verified
- Jul 2026
- First submitted
- 12 Jan 2023
- Last updated
- 13 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Publications
Nolte CH. Factor XI inhibitors - Rising stars in anti-thrombotic therapy? J Neurol Sci. 2024 Sep 15;464:123157. doi: 10.1016/j.jns.2024.123157. Epub 2024 Jul 29.
PubMed 39094433
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- ClinicalTrials.gov ID
- NCT05712200
- Acronym / sponsor ID
- LILAC-TIMI 76 / ANT-010
- Conditions
- Atrial Fibrillation (AF)
- Keywords
- abelacimab, randomized, placebo-controlled, double-blind, endpoint evaluation, atrial fibrillation
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 2,500 participants (estimated)
- Lead sponsor
- Anthos Therapeutics, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Novartis Pharmaceuticals
- Study start
- 27 Dec 2022 (actual)
- Primary completion
- 30 Dec 2027 (estimated)
- Study completion
- 30 Dec 2027 (estimated)
- First posted
- 3 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
Detailed description
Patients enrolled in the study are randomized in a 1:1 ratio to receive abelacimab 150 mg SC or matching placebo once monthly. The study is comprised of 3 periods: 1) screening period of up to 60 days, 2) an event-driven, double-blind treatment period (abelacimab 150 mg SC or matching placebo) completed after at least 111 patients have experienced an adjudicated primary endpoint event, and 3) EoT visit in core part followed by either (i) a 30-day follow-up period (EoS for core part) OR (ii) an optional OLE beginning at the EoT visit for eligible patients to receive open-label abelacimab treatment. The optional extension will only be offered to patients following regulatory and ethics approval in participating countries.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Abelacimab (MAA868) | Experimental | Biological: AbelacimabPatients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly. |
| Placebo | Placebo comparator | Drug: PlaceboPatients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (6 listed)
- Patient is able to understand and has provided written informed consent to participate in the trial
- Diagnosed Atrial Fibrillation (AF) or atrial flutter (documented on an electrocardiogram (ECG) or monitor recording)
- Age 65-74 and a CHA2DS2VASc ≥4 OR age ≥75 and a CHA2DS2VASc ≥3
- Patient is judged by the responsible physician to be unsuitable for oral anticoagulation because the risks outweigh the benefits or the patient is unwilling to take oral anticoagulation AND this determination was made prior to and independent of the study
- At least 1 bleeding risk factor such as severe renal insufficiency, planned daily use of antiplatelet medication for the duration of the trial, history of bleeding from a critical area, or other conditions associated with increased risk of bleeding such as chronic nonsteroidal anti-inflammatory drug (NSAID) use, frailty or multiple falls
Key exclusion criteria (7 listed)
- AF due to an ongoing acute reversible cause (e.g., cardiac surgery, pulmonary embolism (PE), untreated hyperthyroidism, alcohol use)
- Patients who within 60 days prior to randomization (1) received a vitamin K antagonists (VKA) (e.g., warfarin, phenprocoumon, acenocoumarol) or a direct oral anticoagulant (DOAC) such as, dabigatran, rivaroxaban, apixaban, or edoxaban or (2) were newly diagnosed with AF
- Patients with an intracranial or intraocular bleed within the 3 months prior to screening or any history of spontaneous intracerebral hemorrhage at any time in the absence of antithrombotic treatment
- Any stroke within 14 days before randomization or transient ischemic attack (TIA) within 3 days before randomization
- Mechanical heart valve or valve disease that is expected to require mechanical valve replacement intervention (surgical or invasive) during the course of the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AbelacimabAlso: MAA868Abelacimab provided as liquid in vial (150 mg/mL) | Biological | Abelacimab (MAA868) |
| PlaceboDosage Formulation: Liquid (in vial) Dose Strength: Placebo to Abelacimab | Drug | Placebo |
Primary outcome
Efficacy: Time to first event of ischemic stroke or systemic embolism (SE)
Time frame: Up to 30 months
Undetermined strokes will be counted as ischemic strokes
Safety: Time to first occurrence of Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding
Time frame: Up to 30 months
5 secondary outcomes
Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), or acute limb ischemia
Time frame: Up to 30 months
Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), or Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding event
Time frame: Up to 30 months
Efficacy: Cardiovascular (CV) mortality
Time frame: Up to 30 months
Efficacy: All-cause mortality
Time frame: Up to 30 months
Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), acute limb ischemia, or International Society on Thrombosis and Haemostasis (ISTH) major bleeding
Time frame: Up to 30 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2026.
- Derived from this study: PubMed 39094433Nolte CH. Factor XI inhibitors - Rising stars in anti-thrombotic therapy? J Neurol Sci. 2024 Sep 15;464:123157. doi: 10.1016/j.jns.2024.123157. Epub 2024 Jul 29.
- Individual participant dataSharing planned: Yes. Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Related trials for Atrial Fibrillation (AF)
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Atrial Fibrillation (AF)
Not yet recruitingObservational study
Hummingbird ICE Study
ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
789 sites in 35 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Abelacimab in people with Atrial Fibrillation (AF), run by Anthos Therapeutics, Inc. at 789 sites in 35 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 789 sites in United States, China, Brazil, India, Argentina and 30 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Anthos Therapeutics a Novartis Company (1-888-669-6682, novartis.email@novartis.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Efficacy: Time to first event of ischemic stroke or systemic embolism (SE) (time frame: Up to 30 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05712200, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026.